JYONG BIOTECH LTD.
23F-3, No. 95, Section 1, Xintai 5th Road
Xizhi District, New Taipei City
Taiwan, 221
December 20, 2023
Via EDGAR
Division of Corporation Finance
Office of Life Sciences
Securities and Exchange Commission
Washington, D.C. 20549
Ibolya Ignat
Mary Mast
Doris Stacey Gama
Joe McCann
| | Re: | Jyong Biotech Ltd. |
| | | Request for Withdrawal of Registration Statement on Form F-1 |
| | | File No. 333-274042 |
Dear Sir and Madam:
Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), Jyong Biotech Ltd. (the “Company”) hereby requests that the above-referenced registration statements on Form F-1 originally filed on August 17, 2023, including all exhibits filed therewith and amendment thereto (collectively, the “Registration Statement”), be withdrawn, effective as of the date hereof.
The Registration Statement was not declared effective and none of the Company’s securities has been sold pursuant to the Registration Statement. The Company is withdrawing the Registration Statement on grounds that the withdrawal of the Registration Statement is consistent with the public interest and protection of investors, as contemplated by paragraph (a) of Rule 477 of the Securities Act.
In accordance with Rule 457(p) under the Securities Act, the Company requests that all fees paid to the Commission in connection with the filing of the Registration Statement be credited to the Company’s account to be offset against the filing fee for future use by the Company or an affiliate of the Company.
Pursuant to the requirements of Rule 477 under the Securities Act, the Company has duly caused this request for withdrawal to be signed on its behalf by the undersigned, thereunto duly authorized.
| | Very truly yours, |
| | |
| | /s/ Fu-Feng Kuo |
| | Fu-Feng Kuo |
| | Chairman of the Board and Chief Executive Officer |
